Pfizer (NYSE:PFE) Stock Price Up 0.4% – Here’s Why

Pfizer Inc. (NYSE:PFE)’s share price rose 0.4% during mid-day trading on Friday . The company traded as high as $22.55 and last traded at $22.13. Approximately 53,854,504 shares changed hands during trading, an increase of 33% from the average daily volume of 40,458,828 shares. The stock had previously closed at $22.04.

Analyst Ratings Changes

A number of research firms have recently weighed in on PFE. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group lowered their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.07.

Pfizer Stock Up 0.4 %

The business has a fifty day moving average of $24.95 and a 200-day moving average of $26.23. The stock has a market cap of $125.50 billion, a PE ratio of 15.69, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Pfizer

Institutional investors have recently added to or reduced their stakes in the stock. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer in the fourth quarter worth $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $28,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.